Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Follow-Up Questions
Passage Bio Inc (PASG) 的本益比是多少？
Passage Bio Inc 的本益比是 N/A
Passage Bio Inc 的 CEO 是誰？
Mr. William Chou 是 Passage Bio Inc 的 President，自 2022 加入公司。
PASG 股票的價格表現如何？
PASG 的當前價格為 7.21，在上個交易日 decreased 了 4.4%。
Passage Bio Inc 的主要業務主題或行業是什麼？
Passage Bio Inc 屬於 Biotechnology 行業，該板塊是 Health Care
